Tilia Fiduciary Partners Inc. Grows Position in Stryker Co. (NYSE:SYK)

by · The Cerbat Gem

Tilia Fiduciary Partners Inc. raised its position in Stryker Co. (NYSE:SYK – Free Report) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 7,075 shares of the medical technology company’s stock after purchasing an additional 243 shares during the period. Stryker makes up 1.7% of Tilia Fiduciary Partners Inc.’s portfolio, making the stock its 19th biggest position. Tilia Fiduciary Partners Inc.’s holdings in Stryker were worth $2,548,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SYK. State Street Corp lifted its stake in shares of Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after acquiring an additional 316,404 shares during the last quarter. FMR LLC increased its stake in Stryker by 3.0% in the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after purchasing an additional 215,782 shares during the period. Geode Capital Management LLC lifted its position in shares of Stryker by 2.5% during the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company’s stock worth $2,484,893,000 after purchasing an additional 165,490 shares during the last quarter. Clearbridge Investments LLC boosted its stake in shares of Stryker by 2.9% during the second quarter. Clearbridge Investments LLC now owns 2,323,452 shares of the medical technology company’s stock valued at $790,554,000 after purchasing an additional 66,482 shares during the period. Finally, Parnassus Investments LLC bought a new position in shares of Stryker in the third quarter worth about $762,798,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.5 %

NYSE SYK traded up $1.94 on Friday, hitting $366.04. The stock had a trading volume of 1,301,213 shares, compared to its average volume of 1,230,486. Stryker Co. has a 52-week low of $306.10 and a 52-week high of $398.20. The business’s fifty day moving average price is $375.42 and its 200 day moving average price is $357.51. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock has a market cap of $139.54 billion, a price-to-earnings ratio of 39.23, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 EPS. Equities research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is currently 36.01%.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SYK. Robert W. Baird lifted their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $425.00 price objective on shares of Stryker in a research note on Tuesday. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $405.80.

Check Out Our Latest Report on Stryker

About Stryker

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).